Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis
- PMID: 9247479
- DOI: 10.1053/gast.1997.v113.pm9247479
Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis
Abstract
Background & aims: Therapeutic paracentesis may be associated with a circulatory dysfunction, manifested by a marked increase of the plasma renin activity and plasma norepinephrine. The aim of the study was to characterize the systemic and hepatic hemodynamic changes associated with paracentesis-induced circulatory dysfunction.
Methods: Changes in plasma renin, aldosterone, and norepinephrine, and in systemic and hepatic hemodynamics were assessed 1 hour and 6 days after complete mobilization of ascites in 37 patients treated by total paracentesis plus intravenous dextran-70 infusion.
Results: Paracentesis-induced circulatory dysfunction occurred in 10 patients (renin and norepinephrine increased from 9.0 +/- 10.5 to 28.8 +/- 19.0 ng.mL-1.h-1 and from 752.0 +/- 364.0 to 1223.0 +/- 294.0 pg/mL, respectively) and was associated with significant reduction in systemic vascular resistance (-13.0% +/- 2.6%; P < 0.05) and increase in hepatic venous pressure gradient (from 19.5 +/- 1.5 to 22.5 +/- 2.4 mm Hg; P < 0.01). In the remaining 27 patients, mobilization of ascites also induced a significant but smaller reduction in systemic vascular resistance (-5.0% +/- 1.6%; P < 0.05) without significant changes in renin, norepinephrine, and hepatic venous pressure gradient.
Conclusions: Paracentesis-induced circulatory dysfunction is predominantly caused by an accentuation of the arteriolar vasodilation already present in untreated cirrhotic patients with ascites. The homeostatic activation of endogenous vasoactive systems may account for the increased intrahepatic vascular resistance associated with this condition.
Similar articles
-
Hemodynamic changes in patients developing effective hypovolemia after total paracentesis.J Hepatol. 1998 Apr;28(4):639-45. doi: 10.1016/s0168-8278(98)80288-2. J Hepatol. 1998. PMID: 9566833 Clinical Trial.
-
Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study.Dig Dis Sci. 2016 Oct;61(10):3084-3092. doi: 10.1007/s10620-016-4140-3. Epub 2016 Apr 5. Dig Dis Sci. 2016. PMID: 27048451
-
Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites.Am J Gastroenterol. 1997 Mar;92(3):394-9. Am J Gastroenterol. 1997. PMID: 9068457
-
Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence.Can J Gastroenterol Hepatol. 2020 Jun 22;2020:5106958. doi: 10.1155/2020/5106958. eCollection 2020. Can J Gastroenterol Hepatol. 2020. PMID: 32676484 Free PMC article.
-
Paracentesis in the management of cirrhotic ascites.J Hepatol. 1993;17 Suppl 2:S14-8. doi: 10.1016/s0168-8278(05)80449-0. J Hepatol. 1993. PMID: 8491965 Review.
Cited by
-
The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis.Clin Gastroenterol Hepatol. 2012 Oct;10(10):1169-75. doi: 10.1016/j.cgh.2012.06.027. Epub 2012 Jul 16. Clin Gastroenterol Hepatol. 2012. PMID: 22801062 Free PMC article. Clinical Trial.
-
Approach and management of dysnatremias in cirrhosis.Hepatol Int. 2018 Nov;12(6):487-499. doi: 10.1007/s12072-018-9894-6. Epub 2018 Sep 10. Hepatol Int. 2018. PMID: 30203382 Review.
-
Clinical Implications, Evaluation, and Management of Hyponatremia in Cirrhosis.J Clin Exp Hepatol. 2022 Mar-Apr;12(2):575-594. doi: 10.1016/j.jceh.2021.09.008. Epub 2021 Sep 16. J Clin Exp Hepatol. 2022. PMID: 35535075 Free PMC article. Review.
-
IMPACT OF MELD SODIUM ON LIVER TRANSPLANTATION WAITING LIST.Arq Bras Cir Dig. 2019 Dec 9;32(3):e1460. doi: 10.1590/0102-672020190001e1460. eCollection 2019. Arq Bras Cir Dig. 2019. PMID: 31826087 Free PMC article.
-
Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease.Curr Hepatol Rep. 2020;19(3):147-158. doi: 10.1007/s11901-020-00521-1. Epub 2020 Jul 1. Curr Hepatol Rep. 2020. PMID: 32837825 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical